Risk of liver dysfunction with ACE inhibitors based on real-world data from the MID-NET^® in Japan.

ABSTRACT: Warnings about liver dysfunction in Japanese package inserts vary among angiotensin-converting enzyme (ACE) inhibitors, and risk assessment of liver dysfunction with ACE inhibitors has been limited. To evaluate the risk of liver dysfunction among patients prescribed ACE inhibitors available in Japan, we conducted this study based on the real-world data from MID-NET^®. We identified patients who were newly prescribed ACE inhibitors between January 1, 2009 and December 31, 2019 and excluded patients with liver dysfunction before the first prescription of ACE inhibitors. To compare the risk of liver dysfunction between the control group (enalapril maleate) and each exposure group, a pairwise Cox proportional hazards model was employed to estimate the hazard ratio (HR) adjusted by in

SUBMITTER: Kinoshita Y 

PROVIDER: S-EPMC12678171 | biostudies-literature | 2025 Dec

REPOSITORIES: biostudies-literature